374 related articles for article (PubMed ID: 30425195)
1. Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis.
Li ZG; Liu Y; Xu HJ; Chen ZW; Bao CD; Gu JR; Zhao DB; An Y; Hwang LJ; Wang L; Kremer J; Wu QZ
Chin Med J (Engl); 2018 Nov; 131(22):2683-2692. PubMed ID: 30425195
[TBL] [Abstract][Full Text] [Related]
2. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
Wollenhaupt J; Lee EB; Curtis JR; Silverfield J; Terry K; Soma K; Mojcik C; DeMasi R; Strengholt S; Kwok K; Lazariciu I; Wang L; Cohen S
Arthritis Res Ther; 2019 Apr; 21(1):89. PubMed ID: 30953540
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.
Lee EB; Yamanaka H; Liu Y; Tsai WC; Chen C; Kwok K; Yoo HJ; Llamado LJ; Wang L; Luo Y; Sugiyama N; Tanaka Y
Int J Rheum Dis; 2019 Jun; 22(6):1094-1106. PubMed ID: 30900375
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
[TBL] [Abstract][Full Text] [Related]
6. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
Kaine J; Tesser J; Takiya L; DeMasi R; Wang L; Snyder M; Soma K; Fan H; Bandi V; Wollenhaupt J
Clin Rheumatol; 2020 Jul; 39(7):2127-2137. PubMed ID: 32048083
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.
Wollenhaupt J; Silverfield J; Lee EB; Curtis JR; Wood SP; Soma K; Nduaka CI; Benda B; Gruben D; Nakamura H; Komuro Y; Zwillich SH; Wang L; Riese RJ
J Rheumatol; 2014 May; 41(5):837-52. PubMed ID: 24692527
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies.
Burgos-Vargas R; Cardiel M; Xibillé D; Pacheco-Tena C; Pascual-Ramos V; Abud-Mendoza C; Mahgoub E; Rahman M; Fan H; Rojo R; García E; Santana K
Reumatol Clin (Engl Ed); 2019; 15(1):43-53. PubMed ID: 28552437
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
Bird P; Hall S; Nash P; Connell CA; Kwok K; Witcombe D; Thirunavukkarasu K
RMD Open; 2019; 5(1):e000742. PubMed ID: 30886732
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.
Curtis JR; Schulze-Koops H; Takiya L; Mebus CA; Terry KK; Biswas P; Jones TV
Clin Exp Rheumatol; 2017; 35(3):390-400. PubMed ID: 28079500
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 years.
Chopra A; Shobha V; Chandrashekara S; Veeravalli SCM; Sharma R; Rao UR; Pandya S; Wagh S; Kadel JK; Thorat AV; Adhav C; Santos Estrella P; Yu W; Kwok K; Wouters A
Int J Rheum Dis; 2020 Jul; 23(7):882-897. PubMed ID: 32478474
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
Li Z; An Y; Su H; Li X; Xu J; Zheng Y; Li G; Kwok K; Wang L; Wu Q
Int J Rheum Dis; 2018 Feb; 21(2):402-414. PubMed ID: 29314645
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
Takeuchi T; Yamanaka H; Yamaoka K; Arai S; Toyoizumi S; DeMasi R; Fukuma Y; Hirose T; Sugiyama N; Zwillich SH; Tanaka Y
Mod Rheumatol; 2019 Sep; 29(5):756-766. PubMed ID: 30489177
[No Abstract] [Full Text] [Related]
15. Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety.
Bird P; Bensen W; El-Zorkany B; Kaine J; Manapat-Reyes BH; Pascual-Ramos V; Witcombe D; Soma K; Zhang R; Thirunavukkarasu K
J Clin Rheumatol; 2019 Apr; 25(3):115-126. PubMed ID: 29794874
[TBL] [Abstract][Full Text] [Related]
16. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.
Kivitz AJ; Cohen S; Keystone E; van Vollenhoven RF; Haraoui B; Kaine J; Fan H; Connell CA; Bananis E; Takiya L; Fleischmann R
Semin Arthritis Rheum; 2018 Dec; 48(3):406-415. PubMed ID: 30177460
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III.
Cohen SB; Koenig A; Wang L; Kwok K; Mebus CA; Riese R; Fleischmann R
Clin Exp Rheumatol; 2016; 34(1):32-6. PubMed ID: 26575982
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population.
Hall S; Nash P; Rischmueller M; Bossingham D; Bird P; Cook N; Witcombe D; Soma K; Kwok K; Thirunavukkarasu K
Rheumatol Ther; 2018 Dec; 5(2):383-401. PubMed ID: 29949132
[TBL] [Abstract][Full Text] [Related]
20. Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses.
Lomonte ABV; Radominski SC; Marcolino FMD; Brenol CV; Zerbini CAF; García EG; Akylbekova EL; Rojo R; de Leon DP
Medicine (Baltimore); 2018 Aug; 97(31):e11609. PubMed ID: 30075534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]